| Name | Title | Contact Details |
|---|
We are a leading fabless supplier of semiconductor and optical components that enable high speed information streaming and address emerging high growth opportunities in the communications, industrial, defense and avionics industries. The Company offers a broad portfolio of high performance MMIC solutions that enable next generation wireless microwave systems up to 90GHz and drivers, TIAs and TFPS optical modulators for 40G and 100G fiber-optic telecommunications and data-communications networks. GigOptix also offers a wide range of digital and mixed-signal ASIC solutions and enables product lifetime extension through its GigOptix Sunset Rescue Program. GigOptix focuses on the specification, design, development and sale of analog semiconductor Integrated Circuits (ICs), Multi-Chip Module (MCMs) solutions, polymer modulators, and analog and mixed signal custom ASICs, as well as wireless communications MMICs and modules. GigOptix believes it is an industry leader in the fast growing market for electronic solutions that enable high-bandwidth optical connections found in telecommunications (telecom) systems, data communications (datacom) and storage systems, and, increasingly, in consumer electronics and computing systems.
Photonera Corporation is a Sunnyvale, CA-based company in the Computers and Electronics sector.
INTrinsic Semiconductor Corp. is a Sterling, VA-based company in the Computers and Electronics sector.
Viking Modular Solutions is a Foothill Ranch, CA-based company in the Computers and Electronics sector.
Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them. We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.